文献速递中医内科中医骨伤中药与中成药合理使用

中医药防治骨质疏松:从分子机制到药物发现

Traditional Chinese Medicine for osteoporosis management: from molecular mechanisms to drug discovery.
PubMed 文献 · Chin Med · 2026-02-27

该综述聚焦骨质疏松中激素失衡、氧化应激与炎症等复杂发病机制,梳理相关细胞事件与信号通路的分子机制及治疗靶点,并评述仙灵骨葆胶囊、青娥丸等代表性中药复方及淫羊藿苷、柚皮苷、黄芪甲苷IV等成分的临床有效性与作用原理,认为中医药整体观尤其适用于高风险患者。

要点

  • 仙灵骨葆胶囊、青娥丸等复方可通过促进骨形成、抑制骨吸收降低骨折风险。
  • 淫羊藿苷促骨生成、柚皮苷抑制破骨细胞生成、黄芪甲苷IV减轻细胞衰老。
  • 中医药多靶点整体策略尤其适用于骨质疏松高风险患者。

核心结论

  • 中医药整体观为骨质疏松管理提供有价值策略,尤其适用于高风险患者。
  • 传统知识与现代科学结合有助于开发兼顾骨量与骨质量的安全多靶点疗法。

研究设计与样本

  • 综述类文章,围绕骨质疏松的分子机制、治疗靶点、相关细胞事件与信号通路进行汇总。

主要发现

  • 骨质疏松发病涉及激素失衡、氧化应激和炎症等复杂机制。
  • 仙灵骨葆胶囊和青娥丸等代表性中药复方可通过促进骨形成和抑制骨吸收降低骨折风险。
  • 淫羊藿苷增强骨生成,柚皮苷抑制破骨细胞生成,黄芪甲苷IV减少细胞衰老。

临床怎么用

  • 可关注仙灵骨葆胶囊、青娥丸等复方在降低骨折风险方面的应用。
  • 可关注淫羊藿苷、柚皮苷、黄芪甲苷IV等成分促进骨形成、抑制骨吸收及减轻细胞衰老的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Osteoporosis, a prevalent skeletal disorder, poses significant challenges in aging populations. Traditional Chinese Medicine (TCM) offers a multi-target approach to addressing its complex pathogenesis, which involves hormonal imbalance, oxidative stress, and inflammation. This review highlights the current progress in osteoporosis, focusing on the molecular mechanisms and therapeutic targets of relevant mechanisms, as well as the related cellular events and signaling pathways. Furthermore, the study reviews the clinical effectiveness of several representative TCM formulae, such as Xianling Gubao Capsule and Qing'e pill, which can reduce fracture risk by promoting bone formation and suppressing bone resorption. The study also discusses the therapeutic principles of the promising medicinal herbal compounds, such as icariin for enhancing osteogenesis, naringin for inhibiting osteoclastogenesis, and astragaloside IV for reducing cellular senescence. In summary, TCM's holistic approach offers a valuable strategy for managing osteoporosis, particularly for high-risk patients. Integrating traditional knowledge with modern science enables the development of safer, multi-target therapies addressing both bone quantity and quality. Continued research will facilitate evidence-based TCM interventions for global osteoporosis care.

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Yan S, Du Q, Zhao L, et al. Traditional Chinese Medicine for osteoporosis management: from molecular mechanisms to drug discovery. Chin Med. 2026. PMID: 41749251. doi:10.1186/s13020-026-01353-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。